Adma Biologics (ADMA)
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficienci...
- Open
- 9.430
- High
- 9.620
- Low
- 9.390
- Prev. Close
- 9.580
- Volume
- 1.41M
- Turnover
- 13.42M
- Avg Price
- 9.546
- Bid/Ask Ratio
- --
- Amplitude
- 2.40%
- 52wk High
- 20.458
- Volume Ratio
- 0.56
- Turnover Ratio
- 0.62%
Adma Biologics Analyst Rating
View moreForecast & Rating
Aug 6, 2026Price forecast
$17.0076.72%
Forecast & RatingBuy
5analysts
- Strong buy60.00%
- Buy20.00%
- Hold20.00%
- Sell0.00%
- Strong sell0.00%
News
- Market Beat · 1 day ago, 08:40 AM
The Manufacturers Life Insurance Company Buys Shares of 124,383 ADMA Biologics Inc $ADMA
- Market Beat · 2 days ago, 11:06 AM
ADMA Biologics (NASDAQ:ADMA) Stock Rating Upgraded by Zacks Research
- Market Beat · Sep 2 at 10:24 AM
Velan Capital Investment Management LP Invests $2.09 Million in ADMA Biologics Inc $ADMA
- prnewswire · Aug 31 at 06:36 PM
14:35 ETBerger Montague PC Investigates ADMA Biologics, Inc.'s Board of Directors for Breach of Fiduciary Duty (NASDAQ: ADMA)
- Global Report · Aug 25 at 10:11 AM
Tenet and Elmet Drive Mid-2026 Earnings as Aurora Speeds Autonomy
- prnewswire · Aug 21 at 08:40 AM
04:38 ETADMA Investors Have Opportunity to Lead ADMA Biologics, Inc. Securities Fraud Lawsuit with SBS Law
